What is the history of Adrenal Cortical Carcinoma (ACC)?

Adrenal Cortical Carcinoma (ACC) is a rare, aggressive malignancy of the adrenal cortex first documented in the early 19th century, with the first clear clinical description credited to Thomas Blizard Curling in 1845. Over the past two centuries, our understanding has shifted from viewing Adrenal Cortical Carcinoma (ACC) as an autopsy curiosity to a complex, genetically driven disease requiring multidisciplinary management.

How was Adrenal Cortical Carcinoma first identified?

While reports of adrenal tumors appeared in early anatomical literature, the British surgeon Thomas Blizard Curling provided one of the earliest clinical accounts of a large, malignant adrenal tumor in 1845. Initially, these cases were often grouped with other adrenal masses, making it difficult to distinguish Adrenal Cortical Carcinoma (ACC) from benign adenomas. Diagnostic clarity only began to emerge in the early 20th century as endocrinology evolved and the hormonal functions of the adrenal cortex were mapped.

How has our understanding of ACC evolved?

Historically, Adrenal Cortical Carcinoma (ACC) was often misdiagnosed due to the lack of biochemical assays. The mid-20th century brought a breakthrough with the development of steroid hormone testing, allowing clinicians to identify "functional" tumors that secrete excess cortisol or androgens. Modern research has since moved into the molecular realm, identifying key genetic drivers such as the TP53 mutation, which is notably prevalent in pediatric cases of Adrenal Cortical Carcinoma (ACC).

What are the major milestones in treatment?

The management of this disease has undergone significant transformation, particularly with the introduction of systemic therapies:

• 1960s: The discovery of Mitotane, an adrenolytic agent, provided the first effective, albeit toxic, systemic treatment for Adrenal Cortical Carcinoma (ACC).


• 1980s-90s: Advances in surgical techniques, specifically the adoption of radical adrenalectomy, improved outcomes for localized disease.


• 2000s-Present: The integration of the FIRM-ACT trial protocols established the standard chemotherapy regimen (etoposide, doxorubicin, cisplatin, and mitotane).

How has patient advocacy changed the landscape?

Because Adrenal Cortical Carcinoma (ACC) is exceptionally rare—with an estimated annual incidence of 1 to 2 per million people—patients long suffered from isolation. Today, global platforms like DiseaseMaps.org, which hosts 265 members sharing their experiences with Adrenal Cortical Carcinoma (ACC), have become vital for fostering community, accelerating clinical trial enrollment, and humanizing the statistical data.

Next steps

• Consult with an endocrinology-oncology specialist at a high-volume center experienced in treating rare adrenal cancers.


• Connect with the 265 members of the DiseaseMaps.org community to share resources and experiences.


• Discuss genetic counseling with your team, especially if there is a family history of Li-Fraumeni syndrome.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD) - Adrenal Cortical Carcinoma


• Orphanet: Adrenocortical carcinoma (ORPHA:135)


• American Association of Endocrine Surgeons (AAES) - Adrenal Cancer Clinical Guidelines


• OMIM (Online Mendelian Inheritance in Man) - Adrenal Cortical Carcinoma Entry